Cargando…
Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases
Obinutuzumab (G) has become part of front-line treatment of follicular lymphoma (FL) based on results of a large randomized study. Data on patients treated outside of clinical trials are lacking. We have retrospectively investigated efficacy and safety of G-based immunochemotherapy regimens in 114 p...
Autores principales: | Galusic, Davor, Basic-Kinda, Sandra, Pijuk, Andela, Milunovic, Vibor, Dreta, Barbara, Franjic, Neven, Coha, Bozena, Sincic-Petricevic, Jasminka, Gacina, Petar, Pejsa, Vlatko, Lucijanic, Marko, Aurer, Igor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668548/ https://www.ncbi.nlm.nih.gov/pubmed/36407092 http://dx.doi.org/10.1097/HS9.0000000000000807 |
Ejemplares similares
-
P1110: EFFICACY AND SAFETY OF IMMUNOCHEMOTHERAPY IN TREATMENT OF FOLLICULAR NON-HODGKIN’S LYMPHOMA DURING COVID-19 PANDEMIC: A STUDY OF KROHEM, THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES
por: Galusic, D., et al.
Publicado: (2022) -
Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017
por: Jakšić, Branimir, et al.
Publicado: (2018) -
Purine Analogues Increase the Risk of Lethal and/or Prolonged COVID19 While Obinutuzumab Increases the Risk of Prolonged but Not Lethal Infection in Patients Treated for Lymphoid Malignancies -a Study of Krohem, the Croatian Group for Hematologic Diseases
por: Aurer, Igor, et al.
Publicado: (2021) -
Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases
por: Bašić-Kinda, Sandra, et al.
Publicado: (2021) -
P1568: EARLY, BUT NOT LATE USE OF REMDESVIR AND CONVALESCENT PLASMA REDUCES MORTALITY OF COVID 19 IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES – A STUDY OF KROHEM
por: Aurer, I., et al.
Publicado: (2022)